Dr Kimberly Blackwell - Duke University Medical Center, USA
Two targeted therapies - lapatinib plus trastuzumab - are better than one in the fight against HER2-positive metastatic breast cancer. These two targeted therapies against HER2, sort of a 'one-two punch', conveyed a more than four month significant improvement in survival when compared to lapatinib alone. Official San Antonio Breast Cancer Symposium press conference.
Watch Dr Blackwell speaking to ecancertv about the research she is presenting at SABCS 2009.
